425: Quanterix to Provide Akoya Biosciences with $30 Million Convertible Note Financing

Quanterix Corporation will provide Akoya Biosciences with up to $30 million in convertible note financing, contingent on certain milestones and the potential termination of their merger agreement.

Summary

• Quanterix Corporation has entered into a securities purchase agreement with Akoya Biosciences, Inc., agreeing to provide up to $30 million in convertible promissory notes.
• Akoya can draw on these notes between May 15, 2025, and July 9, 2025, or potentially until January 9, 2026, depending on the status of their merger agreement.
• The notes will mature 91 days after the earlier of November 1, 2027, or the date Akoya's existing loan agreement is repaid, and will bear interest at SOFR plus a specified margin.
• Quanterix has the option to convert the notes into Akoya common stock if the merger agreement is terminated, subject to a 19.99% ownership cap prior to stockholder approval.
• Akoya must file a registration statement for the resale of shares issued upon conversion by August 13, 2025.
• The convertible notes will be subordinate to Akoya's existing loan agreement with MidCap Financial Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document outlines a financial agreement with both potential benefits and risks for both parties. The outcome is dependent on the merger agreement and Akoya's future performance.

Positives

• Akoya gains access to potential funding of up to $30 million to support its operations.
• Quanterix secures a potential return on investment through interest payments and potential equity conversion.
• The agreement includes provisions for adjusting the conversion price to protect Quanterix from dilution.

Negatives

• Akoya incurs additional debt, which could strain its financial resources if the merger does not proceed.
• Quanterix faces the risk of Akoya not being able to repay the notes if the merger is terminated.
• The conversion of notes to equity is capped at 19.99% prior to stockholder approval, potentially limiting Quanterix's influence.

Risks

• The merger agreement between Quanterix and Akoya may be terminated, impacting the terms and potential benefits of the financing.
• Akoya may not be able to draw the full $30 million if the merger closes before May 15, 2025.
• Changes in SOFR interest rates could affect the cost of the financing for Akoya and the return for Quanterix.
• Akoya's existing debt with MidCap Financial Trust takes priority over the convertible notes, increasing Quanterix's risk.
• The value of Akoya's common stock could decline, reducing the potential return for Quanterix upon conversion.

Future Outlook

The future is contingent on the merger agreement between Quanterix and Akoya; if the merger proceeds, the convertible note may not be drawn. If the merger is terminated, Quanterix has the option to convert the debt into equity in Akoya.

Industry Context

This announcement reflects a trend of strategic investments and acquisitions within the life sciences and diagnostics industries, where companies are seeking to expand their technology platforms and market reach.

Comparison to Industry Standards

• Convertible note financing is a common tool in the biotech industry, particularly for companies with promising technology but limited current revenue.
• Comparable companies such as Adaptive Biotechnologies and NanoString Technologies have utilized similar financing strategies to fund operations and strategic initiatives.
• The interest rate and conversion terms are within the typical range for convertible notes in the life sciences sector, reflecting the risk and potential upside of the investment.

Stakeholder Impact

• Shareholders of Akoya may experience dilution if the convertible notes are converted into equity.
• Employees of Akoya may benefit from the additional funding, providing greater job security.
• Customers and suppliers of Akoya may see continued operations and potential for growth with the financial support.
• Creditors of Akoya should note the subordination of the convertible notes to existing debt.

Next Steps

• Akoya may draw on the convertible notes between May 15, 2025, and July 9, 2025, or potentially until January 9, 2026, depending on the status of their merger agreement.
• Akoya must file a registration statement for the resale of shares issued upon conversion by August 13, 2025.
• Quanterix and Akoya will continue to pursue the merger agreement, with the convertible note serving as a potential financing option if the merger is terminated.

Key Dates

Keywords

Quanterix, Akoya Biosciences, convertible notes, merger agreement, financing, securities purchase agreement, SOFR, registration rights, subordination agreement, private placement